Aten Therapeutics

What Aten Therapeutics does

Aten Therapeutics is a privately held biotechnology company founded in 2005 and headquartered in London, United Kingdom. The company self-describes as "an innovative biotechnology company," but specific therapeutic areas, pipeline assets, modality focus (small molecule, biologic, cell therapy, etc.), and underlying platform technology are not disclosed in the available source data. The company operates with a very small team of 1-10 employees, and its website (atentherapeutics.com) currently displays only a security verification page, preventing access to any product, scientific, or corporate information.

The company's only documented financial activity is a single grant award of approximately $329,624 from Innovate UK dated 2022-08-30, which constituted non-dilutive research funding. There is no public disclosure of additional funding rounds, partnerships, intellectual property, clinical or preclinical programs, customers, revenue, management team, or scientific advisors. The combination of an extended nominal operating period (founded 2005), a micro headcount, a single small grant, and no publicly verifiable activity in the 18+ months since that award suggests either a dormant operating posture, a pre-revenue stealth operation, or a very early-stage research entity. The business model, customer segments, go-to-market motion, and revenue mechanics are all undefined in the available data.

No technology, product, or pricing details are extractable from the sources. There is no evidence of any active commercial operations, no named customers, no distribution or marketing channels, no certifications or regulatory milestones, and no social media presence documented. Investors and acquirers evaluating this entity should treat the absence of verifiable corporate, scientific, and commercial information as a critical data gap requiring direct diligence with the company.

Name

Aten Therapeutics

Website

https://atentherapeutics.com

Company type

Private

Founded year

2005

Headcount range

1–10 employees

Short description

Aten Therapeutics is a privately held London-based biotechnology company founded in 2005. With 1-10 employees and no publicly disclosed pipeline, technology, or revenue, its only verifiable funding is a 2022 Innovate UK grant of approximately $330,000.

Ownership category

akta.pro rank

Product category

Biotechnology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Biotechnology research
• Therapeutic development
• Drug discovery
• Life sciences
• Preclinical research

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Aten Therapeutics is described in its firmographic profile as an innovative biotechnology company. No specific products, therapeutic candidates, platforms, or services are documented in the available source data because the company website is blocked behind a security verification page and no other source material describes its pipeline or commercial offerings. The only material event on record is a 2022 Innovate UK grant award.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Emerging players

• Antiverse: Welsh early-stage biotech building a computational antibody discovery platform. Comparable as a UK-based, very early-stage biologics-discovery company with similar headcount and a similar gap between ambition and disclosed traction.
• LabGenius: London-based early-stage biotech using machine learning for protein/antibody engineering. Closely comparable geography and stage profile to Aten Therapeutics, with a similar AI/protein-engineering discovery orientation.

Broad incumbents

• Charles River Laboratories: Large US-headquartered CRO offering discovery, safety assessment, and manufacturing services. Comparable as the incumbent services provider that small UK biotechs typically rely on for outsourced R&D.
• Exscientia: Oxford-headquartered AI-driven drug discovery company. Comparable as a UK AI/biotech operator targeting therapeutic discovery, providing a benchmark for what scaled-up UK biotechs in adjacent positioning look like.
• Evotec: Germany-headquartered global contract drug-discovery and development platform serving biotech and pharma. Comparable as the kind of partner — and broad competitive context — for an early-stage UK biotech working on therapeutic discovery.
• BenevolentAI: London-based AI-driven drug discovery company. Comparable as a London biotech applying computational approaches to therapeutic discovery, though at significantly greater scale and capitalisation.
• Isomorphic Labs: London-based Alphabet-backed AI drug discovery company. Comparable as a London-headquartered therapeutic discovery player; serves as a long-term aspirational peer and potential acquirer/partner in the same ecosystem.

Direct peers

• Bicycle Therapeutics: UK-headquartered (Cambridge) clinical-stage biotech developing bicyclic peptide-based therapeutics. Comparable to Aten as a small-to-mid UK therapeutics discovery company, though Bicycle is materially more advanced in capital, pipeline, and clinical development.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights3 records

Customer concentration

• LinkedInlinkedin.com/company/aten-therapeutics-ltd

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aten Therapeutics